Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223077 · ClinicalTrials.gov registry record
Mucosal and Microbiota Changes During Acute Campylobacteriosis
A clinical trial of Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT03223077: Recruiting study of Irritable Bowel Syndrome, sponsored by Mayo Clinic.
NCT03223077 is a study of Irritable Bowel Syndrome that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 150 participants, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03223077, a study of Irritable Bowel Syndrome, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.
Primary Outcome
Number of Subjects Who Develop Irritable Bowel Syndrome After Campylobacter Infection
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-10-31 |
| Est. Completion | 2026-06 |
What NCT03223077 shows while recruiting
NCT03223077 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target.
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT03223077 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03223077 about?
NCT03223077 is a clinical study titled "Mucosal and Microbiota Changes During Acute Campylobacteriosis". Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to un...
What is the current status of trial NCT03223077?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2014-10-31. Estimated completion is 2026-06.
What conditions does trial NCT03223077 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
Who is sponsoring clinical trial NCT03223077?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03223077 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03223077's enrollment target sits among peer trials
150 14th of 47 higher than 33 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI